✦ LIBER ✦

A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia

✍ Scribed by David S.H. Bell

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of simvastatin, an HMG-CoA reduc

✍ Jonathan Isaacsohn; Donald Hunninghake; Helmut Schrott; Carlos A. Dujovne; Rober 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Comparison in patients with type 2 diabe

✍ Tracey McLaughlin; Fahim Abbasi; Cindy Lamendola; Elizabeth Leary; Gerald M. Rea 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Cerivastatin, a new synthetic HMG CO-A r

✍ V.V. Kukharchuk; E.Yu. Solovieva; T.A. Rozhkova; M.G. Tvorogova 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 272 KB

F144 Long-term effect of a HMG-CoA reduc

✍ Hung-Hsiang Liou; Mei-Chyn Liu 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Fluvastatin (Sandoz compound XU 62-320-

✍ S. Rywik; U. Klosiewicz-Latoszek; G. Broda; W.B. Szostak 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 119 KB

101 Cerivastatin—a new HMG-CoA reductase

✍ H. Dietrich; W. Ritter; W. Wingender; S. Unger; K. Ochmann 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 164 KB